原发性肝癌合并肝硬化术后TACE的临床研究

目的探讨肝动脉化疗栓塞(TACE)在预防合并原发性肝癌肝硬化手术后复发及预后的临床意义。方法回顾性分析72例原发性肝癌合并肝硬化行手术切除的资料,根据术后是否行TACE治疗分为预防组42例和对照组30例,分析比较两组的复发率和生存率以评估TACE的预防治疗作用。结果预防组术后1年内复发率低于对照组(P<0.05);两组术后2年的复发率比较差异无显著性(P>0.05)。预防组1年生存率(78.57%)及3年生存率(54.76%)均明显高于对照组(分别为46.67%、20.00%,P均<0.01)。结论肝癌合并肝硬化术后预防性应用TACE治疗对术后1年以上复发率无明显影响,但可以降低1年内的复发率,提高1年、3年生存率。

Clinical study of TACE in prevention of post-operative recurrence for primary liver cancer associated with liver cirrhosis

Objective To investigate the clinical significance of transcatheter arterial chemoembolization (TACE) in preventing post-operative recurrence and in predicting prognosis after hepatectomy for patients with primary hepatic cancer associated with liver cirrhosis. Methods The clinical materials of 72 patients undergone hepatectomy for primary hepatic cancer associated with liver cirrhosis were retrospectively analyzed. The patients were divided into two groups, the preventive group (n=42) and the control group (n=30), according to patients receiving TACE treatment or not. A comparison of the recurrence rate and survival rate between these two groups was done for evaluating the preventive function of TACE. Results In the preventive group, the recurrence rate within one year after operation was lower than that in the control group (P<0.05); there was no statistically significant difference within 2 years after operation (P>0.05). In the preventive group, the one-year survival rate (78.57%) and 3-year survival rate (54.76%) were significantly higher than those in the control group (46.67% and 20.00%, respectively), all P<0.01. Conclusions For patients with primary liver cancer associated with liver cirrhosis, TACE preventive treatment can not decrease the recurrence rate in more than one year after hepatectomy, but it can reduce the recurrence rate within one year, and can elevate the 1- and 3- year survival rate.